Search

for
Search:

Glossary Latanoprost

medication used to treat high eye pressure and promote eyelash growth

Latanoprost is a medication primarily used to treat high pressure inside the eye, such as in glaucoma or ocular hypertension. It is a prostaglandin analog that works by increasing the outflow of fluid from the eye, thereby reducing intraocular pressure. Additionally, Latanoprost has been observed to promote eyelash growth, which has led to its off-label use in some cosmetic applications.

Related Terms

Sort by

Research

30 / 528 results

Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost

research Hypertrichosis and Increased Pigmentation of Eyelashes and Adjacent Hair in the Region of the Ipsilateral Eyelids of Patients Treated with Unilateral Topical Latanoprost

216 citations , October 1997 in “American Journal of Ophthalmology”

This study found that unilateral topical latanoprost use for glaucoma was associated with hypertrichosis and increased pigmentation of eyelashes in the treated eye compared to the untreated eye.

A Randomized Double-Blind Placebo-Controlled Pilot Study to Assess the Efficacy of a 24-Week Topical Treatment by Latanoprost 0.1% on Hair Growth and Pigmentation in Healthy Volunteers with Androgenetic Alopecia

research A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia

81 citations , August 2011 in “Journal of The American Academy of Dermatology”

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

Lack of Efficacy of Topical Latanoprost and Bimatoprost Ophthalmic Solutions in Promoting Eyelash Growth in Patients with Alopecia Areata

research Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata

55 citations , March 2009 in “Journal of The American Academy of Dermatology”

This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.

research Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis

50 citations , December 2009 in “Journal of The European Academy of Dermatology and Venereology”

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

research Hypertrichosis induced by latanoprost

39 citations , April 2001 in “Journal of The American Academy of Dermatology”

This article reviews the side effects of topical latanoprost therapy, particularly the hypertrichosis and pigmentation changes of eyelashes and nearby skin, and reports no new clinical results.

research Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata

36 citations , November 2005 in “Journal of The American Academy of Dermatology”

This article discusses the potential of latanoprost for treating alopecia areata, but notes that well-controlled studies are still needed to confirm its effectiveness.

Effect of Latanoprost on Hair Growth in the Bald Scalp of the Stump-Tailed Macaque: A Pilot Study

research Effect of Latanoprost on Hair Growth in the Bald Scalp of the Stump-tailed Macacque: A Pilot Study

33 citations , January 2002

This study found that daily topical application of 500 microg/ml latanoprost led to moderate to marked hair regrowth in a macaque model of androgenetic alopecia.

research Latanoprost Loaded in Polymeric Nanocapsules for Effective Topical Treatment of Alopecia

33 citations , November 2020 in “AAPS PharmSciTech”

research Lash Ptosis Caused by Latanoprost

31 citations , April 2005 in “American journal of ophthalmology”

This case report identified lash ptosis as a potential complication of latanoprost therapy in a 61-year-old man with ocular hypertension.

research Erosive pustular dermatosis of the scalp following topical latanoprost for androgenetic alopecia

21 citations , January 2015 in “Dermatologic Therapy”

This letter discusses a case of erosive pustular dermatosis of the scalp linked to topical latanoprost use for androgenetic alopecia, but reports no clinical results.

research The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows

20 citations , November 2009 in “European Journal of Dermatology”

This study found that topical latanoprost was not effective in treating alopecia areata in eyebrows and eyelashes.

research Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata

15 citations , May 2017 in “Journal of Dermatological Treatment”

In this study, patients with alopecia areata experienced significant hair regrowth using topical latanoprost, minoxidil, or betamethasone valerate, with the addition of latanoprost enhancing the effectiveness of betamethasone valerate, showcasing these treatments as safe and effective options.

research Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy

12 citations , December 2018 in “Clinical Ophthalmology”

This review summarizes clinical trials and comparative studies showing that latanoprostene bunod 0.024% is effective and safe for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension, detailing its mechanism and side effects while considering its therapeutic role.

Nanostructured Lipid Carriers Loaded with Minoxidil and Latanoprost for Targeted Topical Therapy of Alopecia

research Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia

9 citations , February 2022 in “European Journal of Pharmaceutics and Biopharmaceutics”

This study suggests that a nanostructured lipid carrier formulation delivering minoxidil and latanoprost may enhance effectiveness and tolerability in treating alopecia by targeting hair follicles.

research LC–MS bioanalytical method for simultaneous determination of latanoprost and minoxidil in the skin

9 citations , May 2020 in “Journal of Pharmaceutical and Biomedical Analysis”

This study developed an efficient LC-MS bioanalytical method to simultaneously quantify minoxidil sulphate and latanoprost in skin layers, supporting the formulation of topical treatments for androgenic alopecia.

research Latanoprost-induced Skin Depigmentation

9 citations , November 2017 in “Journal of Glaucoma”

This case report documents a patient experiencing paradoxical depigmentation of the periocular skin after one year of using latanoprost, a finding not previously associated with this medication.

research Repigmentation of hair after latanoprost therapy

9 citations , December 2010 in “Journal of The European Academy of Dermatology and Venereology”

This letter reports repigmentation of hair in patients receiving latanoprost therapy.

research Comparison of efficacy, safety and satisfaction of latanoprost versus minoxidil, betamethasone and in combination in patients with alopecia areata: A blinded multiple group randomized controlled trial

8 citations , October 2022 in “Dermatologic Therapy”

In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.

research Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost

5 citations , July 2014 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas”

Latanoprost eye drops caused excessive hair growth and eyelash whitening in a woman.

research A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Latanoprost for Eyelash Growth in Aesthetic Medicine

2 citations , October 2023 in “Cosmetics”

This study found that applying 0.005% latanoprost topically to eyelashes significantly increased their length and darkened their color in healthy volunteers over three months, without causing any side effects or changes in intraocular pressure compared to a placebo.

research The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial

2 citations , March 2022 in “Dermatologic Therapy”

This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.

research A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata

2 citations , January 2021 in “Indian Journal of Dermatology, Venereology and Leprology”

This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.

research Comparison between the effectiveness of topical Latanoprost and topical Minoxidil in treating Scalp Alopecia Areata in relation to CD8 cell expression: A study using clinical, dermoscopic, and immunohistochemical methods

1 citations , June 2023 in “Jordan Journal of Applied Science - Natural Science Series”

This study found that both topical minoxidil and latanoprost effectively improved hair regrowth in patients with alopecia areata, but minoxidil showed higher efficacy.

research Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost

1 citations , January 2015 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas”

Latanoprost eye drops caused excessive cheek hair growth and eyelash whitening in a woman.

Topical Latanoprost Acid for Female Androgenetic Alopecia: A Pilot Proof-Of-Concept Trial With Mechanistic Evidence of Prostaglandin F2α Receptor Activation

research Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation

July 2026 in “Pharmacological Reports”

In this pilot study, topical latanoprost acid was observed to increase hair count and improve hair follicle structure in women with androgenetic alopecia, with no serious adverse events, suggesting potential for further investigation to confirm its efficacy and safety.

research In Vitro Evaluation of Topical Follicular Delivery of Minoxidil and Latanoprost Co-Entrapped in Lipid Nanocarriers

February 2026

This study found that nanostructured lipid carriers significantly improved the targeted delivery of latanoprost and minoxidil to pilosebaceous units in porcine skin, with latanoprost showing notably higher accumulation.

research Latanoprost

January 2025

research Efficacy of Topical Latanoprost Versus Topical Minoxidil In the Treatment of Alopecia Areata: Clinical and Dermoscopic Study

July 2024 in “International Journal of Medical Arts”

In this study, both topical minoxidil and latanoprost were found to improve dermoscopic features of alopecia areata, with latanoprost showing superior effectiveness; minor side effects included erythema and itching.

research Nanostructured Lipid Carriers Loaded with an Association of Minoxidil and Latanoprost for Targeted Topical Therapy of Alopecia

January 2021 in “Social Science Research Network”

This study suggests that a nanostructured lipid carrier formulation of minoxidil and latanoprost may effectively target hair follicles and enhance drug penetration for alopecia treatment.

research o POSSÍVEL USO DA LATANOPROSTA NA TERAPIA CAPILAR

March 2020 in “Revista Eletrônica da Faculdade de Ceres”

This review discusses the role of latanoprost in hair growth but reports no clinical results; the authors suggest further research to determine its efficacy and optimal treatment regimen.